Literature DB >> 20455867

Established donepezil treatment modulates task relevant regional brain activation in early Alzheimer's disease.

W J McGeown1, M F Shanks, K E Forbes-McKay, G D Waiter, I Elrick, M G Venneri, A Venneri.   

Abstract

Neuroimaging studies of cholinesterase inhibitor (ChEI) treatment in Alzheimer's disease (AD) have shown the different short and long term actions of ChEIs. fMRI studies of the ChEI donepezil have focused on its short to medium term action without exploring the effects of established treatment. In this exploratory study the effect of 20 weeks donepezil treatment on regional brain activity was measured with fMRI in patients with mild AD. Twelve patients with probable AD and nine age-matched controls were assessed with a Pyramids and Palm Trees semantic association fMRI paradigm and an n-back working memory fMRI paradigm. In the patient group only, the assessment was repeated after 20 weeks of treatment. After treatment, differences from normal healthy elderly became more pronounced. There was also a spread of deactivation which at retest was detectable in task relevant areas. Behaviourally, however, there were no significant differences between group baseline and retest scores, with a range of performance probably reflecting variation in drug efficacy across patients. Parametric analyses established that increased behavioural scores at retest correlated significantly with higher activation levels in non task relevant areas. Behavioural stability with donepezil treatment was not paralleled by the pattern of improved task specific brain activation reported in similar studies of other ChEIs. This is arguably related to the different mechanisms of action of the ChEIs and might be a clinical correlate of the reported synaptic upregulation following long term donepezil treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20455867     DOI: 10.2174/156720510791383877

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  6 in total

1.  Effects of cholinesterase inhibitor on brain activation in Alzheimer's patients measured with functional near-infrared spectroscopy.

Authors:  Florian G Metzger; Ann-Christine Ehlis; Florian B Haeussinger; Andreas J Fallgatter; Katja Hagen
Journal:  Psychopharmacology (Berl)       Date:  2015-09-11       Impact factor: 4.530

2.  Memantine for the patients with mild cognitive impairment in Parkinson's disease: a pharmacological fMRI study.

Authors:  Shoji Kawashima; Noriyuki Matsukawa
Journal:  BMC Neurol       Date:  2022-05-13       Impact factor: 2.903

3.  Donepezil combined with natural hirudin improves the clinical symptoms of patients with mild-to-moderate Alzheimer's disease: a 20-week open-label pilot study.

Authors:  De-qiang Li; Yu-ping Zhou; Han Yang
Journal:  Int J Med Sci       Date:  2012-05-07       Impact factor: 3.738

4.  Visualizing Hyperactivation in Neurodegeneration Based on Prefrontal Oxygenation: A Comparative Study of Mild Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls.

Authors:  Kah Hui Yap; Wei Chun Ung; Esther G M Ebenezer; Nadira Nordin; Pui See Chin; Sandheep Sugathan; Sook Ching Chan; Hung Loong Yip; Masashi Kiguchi; Tong Boon Tang
Journal:  Front Aging Neurosci       Date:  2017-09-01       Impact factor: 5.750

5.  Cholinergic Enhancement of Brain Activation in Mild Cognitive Impairment during Episodic Memory Encoding.

Authors:  Shannon L Risacher; Yang Wang; Heather A Wishart; Laura A Rabin; Laura A Flashman; Brenna C McDonald; John D West; Robert B Santulli; Andrew J Saykin
Journal:  Front Psychiatry       Date:  2013-09-17       Impact factor: 4.157

Review 6.  Effects of pharmacological and nonpharmacological treatments on brain functional magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment: a critical review.

Authors:  Elisa Canu; Elisabetta Sarasso; Massimo Filippi; Federica Agosta
Journal:  Alzheimers Res Ther       Date:  2018-02-20       Impact factor: 6.982

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.